For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Deltagen, Inc.

USPTO Granted Patents = 14

% Expired Patents = 92.9

Forward Citations = 13

Loading Chart...

Loading Chart...

9 inventors (with patents filed for the assignee):

Keith D Allen (7 out of 10 patents)

Thomas J Brennan (3 out of 5 patents)

Michael W Leviten (2 out of 11 patents)

4. Christian W Siebel (1 out of 19 patents)

5. Mark R Moore (1 out of 47 patents)

6. Robert D Klein (1 out of 20 patents)

7. William Matthews (1 out of 12 patents)

8. Robert G Wisotzkey (1 out of 1 patent)

9. Catherine Guenther (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 7176346 - SLC19A2 amino acid transporter gene disruptions, and compositions and methods related thereto (2007-02-13),

2. 7164055 - HSPC150-like gene disruptions, compositions and methods related thereto (2007-01-16),

3. 7030291 - CYT28 serpentine receptor disruptions, compositions and methods relating thereto (2006-04-18),

4. 6943277 - Transgenic mice containing stefin homolog protease inhibitor gene disruptions (2005-09-13),

5. 6942995 - Methods of creating constructs useful for introducing sequences into embryonic stem cells (2005-09-13),

6. 6929909 - Gene targeting vectors comprising conditional positive selection markers (2005-08-16),

7. 6909031 - Transgenic mice containing glucagon receptor gene disruptions (2005-06-21),

8. 6858772 - Transgenic mice containing magnesium-dependent protein phosphatase gene disruptions (2005-02-22),

9. 6784335 - Transgenic mice containing BMP gene disruptions (2004-08-31),

10. 6765126 - Transgenic mice containing NPY6-R neuropeptide receptor gene disruptions (2004-07-20),

11. 6762342 - Transgenic mice containing intestinal alkaline phosphatase gene disruptions (2004-07-13),

12. 6730821 - Transgenic mice containing retina-specific nuclear receptor gene disruptions (2004-05-04),

13. 6717032 - Transgenic mice containing DEZ orphan receptor gene disruptions (2004-04-06),

14. 6653526 - Transgenic mice exhibiting increased susceptibility to seizures (2003-11-25),

Deltagen, Inc. is a leading biotechnology company that specializes in drug discovery and development. With a strong focus on innovative solutions and cutting-edge technologies, we aim to accelerate the discovery of new therapeutics for various diseases and improve patient outcomes. Our team of highly skilled scientists and researchers work tirelessly to identify and validate novel drug targets, conduct preclinical studies, and facilitate the transition of potential drug candidates into clinical trials. Visit our website to learn more about our advanced research capabilities and ongoing projects.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

14 Patents

#28 in San Carlos, CA

#5,313 in California

#22,289 in US

#42,168 in the World

San Carlos, CA, United States of America

Deltagen, Inc.

Forward Citations = 13

9 inventors:

Keith D Allen (7 out of 10 patents)

Thomas J Brennan (3 out of 5 patents)

Michael W Leviten (2 out of 11 patents)

4. Christian W Siebel (1 out of 19 patents)

5. Mark R Moore (1 out of 47 patents)

Please report any incorrect information to [email protected]

Loading…